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The molecular carcinogenesis of lung cancer has yet
to be clearly elucidated. We investigated the possible
oncogenic function of SEC62 in lung cancer, which
was predicted based on our previous findings that
lung and thyroid cancer tissue samples exhibited in-
creased Sec62 protein levels. The SEC62 gene locus is
at 3q26.2, and 3q amplification is reportedly the most
common genomic alteration in non–small cell lung
cancer. We analyzed SEC62 mRNA and protein levels
in tissue samples from lung cancer patients by real-
time quantitative PCR, Western blot, and IHC and
found significantly increased SEC62 mRNA and pro-
tein levels in tumors compared with tumor-free tissue
samples from the same patients. Correlation analyses
revealed significantly higher Sec62 levels in tumors
with lymph node metastases compared with non-
metastatic tumors, as well as in poorly compared with
moderately differentiated tumors. On the basis of
these promising results, we examined the role of
Sec62 in cancer cell biology in vitro. Cell migration
assays with lung and thyroid cancer cells showed
distinct stimulation of migration in SEC62-overex-
pressing cells and inhibition of migration in Sec62-
depleted cells. Moreover, we found that SEC62 silenc-
ing sensitized the cells to thapsigargin-induced
endoplasmic reticulum stress. Thus, our results indicate
that SEC62 represents a potential candidate oncogene in
the amplified 3q region in cases of non–small cell
lung cancer and harbors various functions in cancer
cell biology. (Am J Pathol 2012, 180:473–483; DOI:
10.1016/j.ajpath.2011.10.039)Lung cancer is the worldwide leading cause of cancer
mortality, resulting in approximately 1.4 million deaths each
year.1 Despite much effort to develop new diagnostic,2–4
prognostic,5,6 and therapeutic7 strategies, lung cancer
mortality remains high,8 with the 5-year survival rate remain-
ing markedly below 20%. However, during the last decade,
several key elements were identified that play crucial roles
in the molecular carcinogenesis of lung cancer,9–11 provid-
ing promising starting points for future research.
Among these, an amplification of the chromosomal
region 3q was identified as the most frequent genomic
alteration in non–small cell lung cancers (NSCLCs).12,13
This amplification seems to be more characteristic of
squamous cell carcinoma (SCC) than of adenocarcinoma
(AC)14,15 and has also been observed in numerous other
tumor entities.16–19 Therefore, many studies focused on
identifying candidate oncogenes within this region, pro-
posing various genes, including PIK3CA, SOX2, RAP2B,
FXR1, and EVI1,20–23 to be potential driver oncogenes on
3q. However, many of these studies either were limited by
a low number of cases or lacked confirmation by func-
tional approaches.
We recently described a 3q gain in prostate cancer
and identified SEC62, a gene encoding for an endoplas-
mic reticulum (ER) transmembrane protein, as the most
commonly overexpressed gene within this region based
on increased mRNA levels.24 Further investigations re-
vealed higher Sec62 protein contents in prostate cancer
cell lines and in prostate cancer tissue samples.25 In
addition, we demonstrated that Sec62 had an essential
function in cell migration25 and in ER stress tolerance of
prostate cancer cells.26 In a multitumor TMA, we found
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AJP February 2012, Vol. 180, No. 2179 of 187 lung cancer samples to be Sec62 positive,
whereas none of 10 examined normal lung tissue sam-
ples showed Sec62 immunoreactivity.25 On the basis of
these promising results, in our present study we analyzed
the Sec62 mRNA and protein levels in 140 tissue samples
from 70 NSCLC patients by quantitative PCR (qPCR),
Western blot, and immunohistochemistry (IHC). In addi-
tion, we performed in vitro experiments to further examine
the functional role of Sec62 in tumor cell biology.
Materials and Methods
Cell Culture and Tissue Samples
Cell lines A549 [Deutsche Sammlung von Mikroorganis-
men und Zellkulturen (German Collection of Microorgan-
isms and Cell Cultures) (DSMZ) number ACC 107], BC01
(kindly provided by G. Unteregger), BHT101 (DSMZ
number ACC 279), ML1 (DSMZ number ACC 464), and
HEK293 (DSMZ number ACC 305) were cultured at 37°C
in Dulbecco’s modified Eagle’s medium (Gibco Invitro-
gene, Karlsruhe, Germany) containing 10% fetal bovine
serum (FBS) (Biochrom, Berlin, Germany) and 1% peni-
cillin/streptomycin (PAA, Pasching, Austria) in a humidi-
fied environment with 5% CO2. The cell line H1299
(American Type Culture Collection number CRL-5803D)
was cultured in RPMI 1640 medium (PAA) containing the
same supplements. Stably transfected cell lines were
cultured in normal culture medium containing 1% G418
(Gibco Invitrogene).
Tissue samples were obtained from 70 lung cancer
patients with pathologically confirmed AC or SCC, dis-
sected by a pathologist, sorted into cancerous and
healthy portions, snap frozen, and stored at 80°C. Ad-
ditional formalin-fixed, paraffin-embedded (FFPE) tissue
samples of the same resectate were stored at room tem-
perature. Tumor samples, as well as tumor-free samples,
from 10 thyroid cancer patients were obtained from sur-
gical FFPE resectates and also stored at room tempera-
ture. SEC62 expression in the tumor tissue was com-
pared with histologically tumor-free tissue of the same
patient. Only samples from patients who gave signed
informed consent were used, following the guidelines of
the local ethics board.
Real-Time qPCR
For each fresh-frozen tissue sample, 5-m cryostat sec-
tions were made and H&E stained before downstream
analyses (qPCR and Western blot) to ensure tumor cell
content above 80% and to exclude excessive contami-
nation with inflammatory cells. For each FFPE sample,
3-m sections were prepared and H&E stained for the
same purpose. In the cases of lung tissue, 20 (tumor) or
40 (tumor-free lung tissue) mg of fresh frozen tissue was
homogenized in liquid nitrogen under sterile conditions,
and consecutive total RNA isolation was performed using
the illustra triplePrep kit (GE Healthcare, Chalfont St.
Giles, England) according to the manufacturer’s instruc-
tions. After purification and concentration with the RNA
Clean & Concentrator kit (Zymo Research, Irvine, Califor-nia), 5 g of the yielded total RNA was reverse tran-
scribed using Superscript 2 RT (Invitrogen, Carlsbad,
California) and Oligo(dT)12-18 primers (Invitrogen). The
resultant cDNA was purified with the PCR Purification Kit
(Qiagen, Hilden, Germany) and adjusted to a final con-
centration of 50 ng/L. RNA isolation from FFPE macro-
scopically dissected tumor tissue was performed with
three to four 10-m sections using the RNeasy FFPE kit
(Qiagen). RNA was analyzed for sufficient quality using
Agilent RNA 6000 Nano Chips (Agilent Biotechnologies,
Waldbronn, Germany). According to previously pub-
lished data, the RNA isolated from our samples was ap-
plicable for qPCR27–29 (see Supplemental Table S1 at
http://ajp.amjpathol.org). Subsequently, reverse tran-
scription was performed using the High Capacity RNA to
cDNA kit (Applied Biosystems, Foster City, California),
and the resultant cDNA was adjusted to a final concen-
tration of 50 ng/L. Real-time qPCR was performed with
TaqMan Gene Expression Assays (Applied Biosystems)
for SEC62 (Hs00541815_s1), GUSB (-glucuronidase,
Hs99999908_m1), and ACTB (-actin, Hs00357333_g1)
in a StepOne Plus 96-well system (Applied Biosystems)
using 50 ng (fresh-frozen tissue) or 100 ng (FFPE tissue)
cDNA per well in a 20-L total reaction volume. Each
sample was tested in triplicate. Gene expression was
calculated as SEC62 expression in the tumor relative to
that in the histologically tumor-free lung tissue of the
same patient, using the CT method and GUSB (lung
cancer) or ACTB (thyroid cancer) as an internal control.30
To ensure the use of a reliable internal control, we
tested 5 genes that had been previously reported as
appropriate internal controls31–33 for their stability in 48 of
our fresh frozen lung tissue samples. In addition to GUSB
and ACTB, we tested POLR2A (RNA polymerase 2,
Hs00172187_m1), GAPDH (glyceraldehyde-3-phosphate-
dehydrogenase, Hs99999905_m1), and TBP (TATA box-
binding protein, Hs00427620_m1). GUSB proved to be the
best candidate for an internal control in lung tissue because
it showed themost stable expression level (see Supplemen-
tal Figure S134 at http://ajp.amjpathol.org).
Protein Quantification of Sec62 in Lung Tissue
and Cell Culture Using Western Blot
From each frozen sample, three 20-m sections were
suspended in 300 L of lysis buffer (20 mmol/L Tris-HCl,
pH 7.4, 150 mmol/L NaCl, 1.5 mmol/L EDTA, 3% glycerol,
1% NP-40) and incubated on ice for 30 minutes. After
addition of 300 L of 2 sample buffer (60 mmol/L Tris-
HCl, pH 6.8, 2% SDS, 10% glycerine, 5% -mercapto-
ethanol, 0.05% bromophenol blue), the samples were
incubated for 5 minutes at 37°C, homogenized in the
presence of glass beads (Sigma Aldrich Chemie GmbH,
Taufkirchen, Germany; diameter between 425 and 600
m) for 30 minutes, and again incubated for 10 minutes
at 56°C. After centrifugation at 16,800  g for 10 minutes
at 4°C, 20, 25, and 30 L of the supernatant were used
for Western blot analysis using an affinity-purified anti-
body directed against the COOH-terminal undecapep-
tide of human Sec62 protein and an affinity-purified poly-
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N-terminus of human -actin (Cell Signaling Technology,
Danvers, MA). To quantify Sec62 in lysate from cultured
cells, 2  105 cells were used for Western blot analysis,
using the described primary antibodies and an anti-
GAPDH antibody from rabbit (Santa Cruz Biotechnology
FL-335). The primary antibodies were visualized with an
ECL Plex goat-anti-mouse IgG-Cy3 or goat-anti-rabbit IgG-
Cy5 conjugate (GE Healthcare) and the Typhoon-Trio im-
aging system (GE Healthcare) and analyzed with Image
Quant TL software 7.0 (GE Healthcare). A ratio of Sec62 to
-actin or GAPDH was determined, respectively. The spec-
ificity of the anti-Sec62 antibody was confirmed previously
under denaturing and native conditions.26
IHC Analysis of Sec62 Protein Levels
Tissue samples from each of the 70 NSCLC cases (35 AC
cases and 35 SCC cases) were previously H&E stained
and evaluated by a pathologist; representative FFPE
blocks of the primary tumor resectate were available from
all 70 cases, and those of directly adjacent histologically
tumor-free lung tissue were available from 30 cases. In
the same way, all 10 thyroid cancer samples were sub-
jected to pathologic evaluation. Three of these were
pathologically classified as follicular carcinomas and
seven as papillary carcinomas. Sections (3 m) were
transferred onto Superfrost Ultra Plus Microscope Slides
(Menzel-Gläser, Braunschweig, Germany) and dried in
the incubator at 37°C overnight.
On deparaffinization, heat-induced epitope retrieval
was performed by microwave treatment in 10 mmol/L
citrate buffer (pH 6.0), and nonspecific protein binding
sites were blocked by incubation in blocking solution [80
mL of 0.1M Tris-HCl, pH 7.2, 3 g of bovine serum albumin
(Sigma Aldrich Chemie GmbH), and 20 mL of FBS
(Sigma Aldrich Chemie GmbH)] for 30 minutes at room
temperature. Subsequently, primary antibody incubation
was performed with a 1:200 solution (diluted in PBS/0.3%
BSA) of a specific Sec62 polyclonal rabbit antibody for 1
hour at room temperature. Each staining series included
a positive control and two negative controls (either with-
out primary antibody or with incubation in a 1:200 solution
of the preimmune serum). Visualization was performed
using the DAKO Real Detection System (DAKO, Glostrup,
Denmark) according to the manufacturer’s instructions,
and slides were counterstained with hematoxylin. Sec62
immunoreactivity was co-evaluated independently by a
reference pathologist for lung diseases, using the Immu-
noreactive Score (IRS) according to Remmele and
Stegner35 as a well-established and unbiased semiquan-
titative validation system. In this system, staining intensity
is classified as no staining (0), weak (1), intermediate (2),
or strong (3) staining. The number of stained cells is
classified as no stained cells (0), below 10% (1), 10% to
50% (2), 51% to 80% (3), or more than 80% (4). The
product of the scores for staining intensity and number of
stained cells is defined as the IRS. Scores of 0 to 2 were
valued as negative, 3 to 4 as weak, 6 to 8 as moderate,
and 9 to 12 as strong.Immunofluorescence Staining
Immunofluorescence double staining was performed on
3-m paraffin sections of tumor-free lung tissue, AC, and
SSC. Deparaffinization, rehydration, and blocking of un-
specific binding sites were performed as previously de-
scribed. The samples were incubated with specific anti-
bodies against Sec62 and Sec61 and visualized by
secondary antibodies labeled with different fluorescent
dyes (anti-rabbit fluorescein isothiocyanate or anti-rabbit
Cy3; Dianova, Hamburg, Germany).
Silencing of Gene Expression by siRNA
For gene silencing, cells were seeded at concentrations
of 1.2  105 cells per well in 12-well plates or 2.4  105
cells per well in six-well plates. The cells were transfected
with SEC62 untranslated region directed small interfering
RNA (siRNA) (5=-CGUAAAGUGUAUUCUGUACdTdT-3=;
Ambion, Austin, TX), SEC62 siRNA (5=-GGCUGUGGC-
CAAGUAUCUUdTdT-3=; Ambion), or control siRNA (All-
Stars Negative Control siRNA; Qiagen) using HiPerFect
Reagent (Qiagen) following the manufacturer’s instruc-
tions. After 24 hours the medium was changed and the
cells were retransfected. Silencing was evaluated using
Western blot analysis. The maximum silencing effect was
seen 72 hours after the first transfection.
Plasmid Transfection
For overexpression of plasmid encoded SEC62, 1.2 
105 cells per well in 12-well plates or 2.4  105 cells per
well in six-well plates were transfected with either an
IRES-GFP-SEC62 plasmid or with the IRES-GFP-LV plas-
mid (LV plasmid) as a negative control using FuGene HD
Reagent (Qiagen) following the manufacturer’s instruc-
tion. Overexpression of the plasmid encoded gene was
evaluated using Western blot analysis. The maximum
overexpression effect was seen 72 hours after plasmid
transfection. For stable transfection, cells were trans-
fected as described, and after 72 hours, medium was
changed to normal culture medium containing 1% G418,
and cells were further cultured until a selection of the
cultured cells was reached. Then cells were harvested,
diluted to a density of 1 cell per 100 L, and 100 L per
well was seeded to a 96-well plate in medium containing
1% G418. Clones originating from a single cell were
selected and analyzed with respect to Sec62 protein
content.
Real-Time Cell Analysis
For the real-time analysis of cell proliferation, the xCEL-
Ligence SP system (Roche Diagnostics GmbH, Mann-
heim, Germany) was used. Cells were pretreated with
siRNA as described or left untreated and after 48 hours
1.0  104 or 2.0  104 cells were seeded into a 96-well
ePlate (Roche Diagnostics GmbH) according to the man-
ufacturer’s instructions. Cell proliferation was monitored
for 72 hours.
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Cells were pretreated with control siRNA or SEC62 siRNAs,
and a total of 2.5  104 cells were seeded in a 24-well BD
Falcon FluoroBlok system (BD, Franklin Lakes, NJ) in
normal medium containing 0.5% FBS. The inserts were
placed in medium with 10% FBS as a chemoattractant.
After 72 hours, the cells were fixed with methanol and
stained with DAPI, and migrating cells were analyzed by
fluorescence microscopy.
Statistical Analysis
For statistical analysis, a Mann-Whitney U-test was used
with SPSS software, version 17.0 (IBM, Chicago, IL), and
XLStat Pro (Addinsoft, New York, NY). P  0.05 was
considered statistically significant.Results
SEC62 mRNA and Protein Levels Are
Frequently Increased in NSCLC
To examine the SEC62 expression pattern in NSCLC, we
analyzed SEC62 mRNA and protein levels by qPCR, West-
ern blot, and IHC in 140 tissue samples from 70 NSCLC
patients. The analysis of SEC62 mRNA content revealed in
60.9% of all cases (P 0.05) a more than 1.5-fold increase
in SEC62 expression in tumor tissue relative to histologically
tumor-free lung tissue of the same patients. We also found
a distinct difference in SEC62 gene expression between the
two histologic subtypes (Figure 1, A and C). Although
87.1% of SCCs showed a significant SEC62 overexpression
(P 0.01), this was true for only 36.4% of the analyzed ACs.
As shown in Figure 1C, most SCCs were characterized by
Figure 1. Analysis of SEC62 mRNA and protein
content using qPCR and Western blot. A: Total
RNA of tumor tissue and tumor-free tissue de-
rived from patients with confirmed cancer was
isolated and reverse transcribed, and SEC62
mRNA content was analyzed by real-time qPCR.
The box plots illustrate the obtained Sec62 CT
values plotted against the examined tissue types
as indicated. A lower CT value indicates an in-
crease in the respective mRNA content. *P 
0.05, **P  0.01, and ***P  0.001. Each box
represents the range from the first quartile to the
third quartile. The median is indicated by a line,
and the mean by a point. The lines outside the
boxes represent the ranges of each group within
the 1.5-fold interquartile range. B: The quantifi-
cation of Sec62 protein level was performed us-
ing Western blot analysis. The amount of Sec62
and -actin (loading control) was quantified and
a ratio of Sec62/-actin was calculated. The
mean values of these ratios were compared be-
tween tumor tissue and tumor-free tissue de-
rived from patients with confirmed cancer. Sta-
tistical analysis using a Mann-Whitney U-test
showed a significant difference between tumor
and tumor-free lung tissue. The data were pre-
sented as described in A. C: The SEC62 mRNA
content was normalized to GUSB as a reference
gene, and an n-fold increase in tumor relative to
tumor-free tissue (2-CT) was calculated for
each patient. SCC and AC patients were grouped
with respect to 2-CT value, and the number of
patients in each group is shown in the upper
panel. Relative Sec62 protein content in tumor
compared with tumor-free tissue was calculated
for each patient as rSec62  [Sec62(tumor)/-
actin(tumor)]/[Sec62(lung)/-actin(lung)]. Pa-
tients were grouped with respect to rSec62, and
values for SCC (white bars) and AC (gray bars)
are shown in the lower panel.
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level, whereas most ACs had a lower than 1.5-fold relative
SEC62 expression.
Next, we analyzed the Sec62 protein levels using
Western blot (Figure 1B) and found a significantly in-
creased Sec62 content in tumor tissue compared with
histologically tumor-free tissue from the same patients
(P  0.0001). Significance was also reached for SCC
(P  0.0002) and AC (P  0.02) separately, with a more
than 1.6-fold increased Sec62 level in 89% of SCCs and
71% of ACs. Corresponding to the qPCR data, most SCCs
had a relative Sec62 score higher than 3, whereas the
relative Sec62 scores for most ACs ranged from 1.5 to 3.
Moreover, Sec62 protein content was evaluated by
IHC again, showing a significantly elevated Sec62 pro-
tein level in all lung tumors (P  0.001) and in SCCs (P 
0.001) and ACs (P  0.001) separately (Figure 2).
To investigate the linkage between SEC62 overex-
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(n=35)number of SEC62 and PIK3CA (located on 3q) with that
of TOP2B (located on 3p) using GAPDH as a reference
gene in tumor and normal lung tissue derived from five
patients with (all SCC patients) and five patients with-
out (four AC patients and one SCC patient) SEC62
overexpression in the tumor by real-time qPCR.36 In
tumor tissue with increased SEC62 mRNA, we found a
twofold to fourfold copy number increase of the SEC62
gene (mean, 2.8-fold), whereas the non–SEC62-over-
expressing tumors showed no copy number increase
(mean, 1.2-fold). Also, for PIK3CA, we found a moder-
ate copy number increase in the SEC62-overexpress-
ing tumors (mean, 1.7-fold), which could not be seen
within nonoverexpressing tumors (mean, 1.0-fold). For
TOP2B, neither SEC62 overexpressing nor nonoverex-
pressing tumors showed an increased copy number,
indicating the specificity of this phenomenon for the




AC (n=35) lung (n=30)
5 (14%) 27 (90%)
13 (37%) 3 (10%)
12 (35%) 0 (0%)
5 (14%) 0 (0%)
Figure 2. IHC analyses reveal a significant and
specific increase of Sec62 protein content in
NSCLC tissue. A: IHC and immunofluorescence
double staining were performed on 3-m FFPE
tissue sections. The number of patients classified
to a specific IRS is indicated by the number of
circles and plotted against examined histologic
subtypes. IRSs were calculated according to the
method of Remmele and Stegner35 (the portion
of tumor cells showing a positive reaction times
the intensity of Sec62 staining). Statistical analy-
sis using a Mann-Whitney U-test revealed a sig-
nificant difference among the individual groups.
*P  0.05, **P  0.01, and ***P  0.001. B: On
the basis of the IRS, samples were subdivided
into groups showing negative (IRS, 0-2), weak
(IRS, 3-4), moderate (IRS, 6-8), or strong (IRS,
9-12) staining. C: Representative images (origi-
nal magnification, 100) of the Sec62-immuno-
stained and corresponding H&E-stained tissue
sections for SCC, AC, normal peripheral lung
tissue, and normal bronchial epithelium, respec-
tively, are shown. The strong (SCC) or weaker
(AC) red staining indicates the Sec62-positive
staining. We note that in the bronchial epithe-
lium the plasma cells in all our experiments
showed strong Sec62 staining (red stained cells)
and therefore served as an internal positive con-
trol for the immunostaining reaction. D: Paraffin
sections (3 m thick) of tumor-free lung tissue,
AC, and SCC were incubated with specific anti-
bodies against Sec62 and Sec61 and visualized
by secondary antibodies labeled with different
fluorescent dyes. Fluorescein isothiocyanate in
the case of Sec62 leads to a green staining (first
column) and Cy3 in the case of Sec61 leads to
a red staining (second column). DNA staining
with DAPI indicates the cell nuclei (third col-
umn). In the fourth column a yellow staining
of the cytoplasm indicates a similar content of
Sec62 and Sec61, whereas the green staining in
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increase of SEC62 mRNA and protein level and not on a
general expansion of the ER, we analyzed the expression
levels of different subunits of the Sec61 complex, the key
element of the ER protein translocation machinery, using
Western blot, qPCR, and immunofluorescence double
staining (Figure 2D; see also Supplemental Figure S3 at
http://ajp.amjpathol.org). We detected no significant el-
evation of the SEC61 expressions in tumor compared
with tumor-free samples. Although Sec62 and Sec61
showed almost equivalent immunofluorescence signals
in tumor-free lung tissue, the Sec62 signal dominated
clearly in ACs and even more in SCCs. This finding indi-
cates that the observed increase in Sec62 protein con-
tent is not due to a global ER expansion. In summary,
increased SEC62 mRNA and protein levels are common
in NSCLC, with emphasis on SCC.
Increase in Sec62 Protein Content Correlates
with the Occurrence of Lymph Node
Metastases and Dedifferentiation of Tumor Cells
We found no correlation between Sec62 protein and
mRNA levels and tumor size (T staging) or with patient
age or sex. Although not statistically significant, we ob-
served a trend toward higher Sec62 levels in advanced
cases by comparing the qPCR and Western blot data
with the clinical stage of disease (data not shown). A
statistically significant correlation was observed between
increased Sec62 protein level and the appearance of
lymph node metastases (N), compared with nonmetas-
tasized tumors (N0), for lung tumors as a whole (P 
0.05) and for SCCs separately (P  0.005; Figure 3).Furthermore, poorly differentiated tumors (G3) compared
with moderately differentiated tumors (G2) were charac-
terized by higher Sec62 protein levels. Again, this was
true for lung tumors in general (P  0.005) and for SCCs
separately (P  0.001) but not for ACs. Corresponding
correlation analyses of the IHC and qPCR data showed
similar tendencies.
Elevated SEC62 mRNA and Protein Levels
Might Also Be Characteristic Features of
Thyroid Cancer
In our previous multitumor TMA, a positive Sec62 reaction
was observed in 92% of follicular and papillary thyroid
carcinomas, whereas only 19% of thyroid adenomas and
14% of normal thyroid tissue were Sec62 positive.25 Mul-
titumor TMAs are sensitive to sampling errors because of
the small sizes of tissue specimens; therefore, in the
present study we confirmed these results with a detailed
analysis of 10 thyroid cancer cases (seven with papillary
and three with follicular differentiation) using qPCR and
IHC (Figure 4).
Four cases showed an increased SEC62 mRNA level,
and six cases showed an elevated Sec62 protein content
in cancerous samples compared with tumor-free tissue
samples from the same patient (overexpression 1.5 for
qPCR or difference 2 in IRS for IHC). As in lung cancer,
elevated Sec62 protein content seemed to correlate with
advanced disease because five of the six tumors with
elevated Sec62 protein levels showed characteristic fea-
tures of invasive growth, including lymph node metasta-
ses, invasion of lymph and blood vessels, or excessive
infiltration of the thyroid capsule; these features were not
Figure 3. Sec62 protein level significantly corre-
lates with the occurrence of lymph node metasta-
ses and dedifferentiation of tumor cells. The cor-
relation between Sec62 protein levels in the tumor
samples with clinical and pathologic data of the
included patients was analyzed. *P  0.05, **P 
0.01, and ***P  0.001. A: For NSCLC as a whole
(P  0.05) and SCC separately (P  0.005), we
found a significantly higher Sec62 protein level,
calculated as rSec62 [Sec62(tumor)/-actin(tu-
mor)]/[Sec62(lung)/-actin(lung)], in tumors
showing lymph node metastases (N) com-
pared with in nonmetastasized tumors (N). B:
Poorly differentiated tumors (G3) showed a
markedly higher Sec62 protein content com-
pared with moderately differentiated tumors
(G2). Again, this was true of NSCLC as a whole
(P  0.005) and SCC (P  0.001).
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levels. In particular, the most advanced thyroid tumor
according to the mentioned characteristics showed a
more than fivefold overexpression of SEC62 mRNA and
strong staining of all cancer cells in IHC, whereas the
tumor-free tissue sample almost lacked Sec62 immuno-
reactivity (Figure 4). Although not as consistent as in
NSCLC, these data suggest a pathogenetic role of Sec62
in the molecular carcinogenesis of a subset of follicular
and papillary thyroid carcinomas, which together ac-
count for more than 80% of thyroid cancers.
Migration Potential and ER Stress Tolerance of
Lung and Thyroid Cancer Cells Strongly
Depend on Sec62 Protein Level
In a next step, we wanted to find out how cancer cells
may profit from an increased Sec62 protein level. On the
basis of the correlation data and previous reports of ER
stress being a common finding in cancer cells,37,38 we
performed functional cell culture experiments to investi-
gate the functions of Sec62 in cell migration and ER
stress tolerance.
Our previous findings in prostate cancer cell lines
demonstrated that silencing of SEC62 mRNA led to dis-
tinct inhibition of the migration potential.26 We found that
SEC62 silencing also inhibited the capability to migrate in
lung (BC01) and thyroid (BHT101 and ML1) cancer cell
lines without affecting cell proliferation (Figure 5). After
demonstrating the essential function of SEC62 in cell
migration, we next wanted to test whether an overexpres-
sion of SEC62 would stimulate migration of an otherwise
nonmigrating cell. We used human embryonic kidney
cells (HEK293) stably transfected with either LV plasmid




Cselected two cell populations with different Sec62 proteinlevels (G2 and D4 cells) compared with 100% in LV cells.
Indeed, cells with an increased Sec62 protein level
showed stronger migration in a 72-hour period compared
with the control cells. The migration of G2 cells (731%
Sec62) was stimulated most, followed by D4 cells (350%
Sec62) (Figure 5). Analyzing the proliferation behavior of
the same cells using the xCelligence system, we found
no significant difference. Thus, these results indicate that
migration is markedly stimulated by SEC62 overexpres-
sion, as was suggested by our finding of a higher Sec62
level in metastasized compared with nonmetastasized
NSCLCs.
Moreover, real-time proliferation data clearly showed
that Sec62 is essential for the ER stress tolerance of lung
and thyroid cancer cells because RNA interference–
based Sec62 depletion led to a markedly reduced pro-
liferation rate up to cell death under the condition of
thapsigargin-induced ER stress (see Supplemental Fig-
ure S4 at http://ajp.amjpathol.org).
Discussion
SEC62 Is a Promising Candidate Oncogene
within the Frequently Amplified Terminal 3q
Region in NSCLCs
The qPCR, IHC, and Western blot analyses of lung can-
cer tissue samples showed significantly increased Sec62
protein (P 0.0001) and mRNA levels (P 0.05) in tumor
tissue compared with tumor-free lung tissue from 70 lung
cancer patients. Multiple reports described 3q amplifica-
tion, particularly within the region from 3q22 to 3qter, as
the most common genomic alteration in NSCLC.12,13 The
SEC62 gene is located at 3q26.2, and the results of our
study suggest that SEC62 is a promising candidate on-
Figure 4. Analysis of SEC62 mRNA and protein
content in thyroid cancer tissue by qPCR and
IHC. A: IHC was performed on 3-m FFPE tissue
sections. For each examined case, the IRS was
calculated according to the method of Remmele
and Stegner35 (the portion of tumor cells show-
ing a positive reaction times the intensity of
Sec62 staining). The IRSs of Sec62 immuno-
stained tumor samples (gray bar) and corre-
sponding tumor-free thyroid tissue samples from
the same patient (white bar) are depicted. B:
Total RNA of tumor tissue and tumor-free tissue
derived from 10 patients with confirmed cancer
was isolated and reverse transcribed, and SEC62
mRNA content was analyzed by real-time qPCR.
The SEC62 mRNA content was normalized to
ACTB as a reference gene, and an n-fold in-
crease in tumor relative to tumor-free tissue (2-
CT) was calculated for each patient. Each sam-
ple was analyzed in triplicates. C: Representative
images (original magnification, 100) of the
Sec62-immunostained and corresponding H&E-
stained tumor-containing and tumor-free tissue
sections are shown for one case with strong
(case 10) and one case with moderate (case 6)
Sec62 protein content increase in the tumor,
respectively.cogene within the 3q area. This hypothesis is supported
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to be particularly characteristic of SCC compared with
AC of the lung.14,15 In addition, a comparison of SEC62
overexpressing with nonoverexpressing tumors revealed
a twofold to fourfold copy number increase for SEC62 in
the overexpressing tumors but not in the nonoverex-
pressing tumors, indicating a link between 3q amplifica-
tion and SEC62 overexpression. We also found SEC62
mRNA and protein levels to be elevated more often and
to a higher degree in SCC than in AC. Furthermore, not
only is 3q amplification described in NSCLC, but it also
seems to be a common feature in various human cancer
entities, predominantly SCCs,16–19 suggesting that 3q
harbors protooncogenes.
On the basis of the data yielded by quantitative anal-
ysis of SEC62mRNA and protein levels in tissue samples,
we performed correlation analyses between the Sec62
concentrations and clinical data sets of the study pa-
tients. We found that significantly increased Sec62 con-
tent correlated with tumors with lymph node metastases
compared with nonmetastasized tumors, as well as with
poorly differentiated tumors (G3) compared with moder-
ately differentiated tumors (G2). These correlations were
more evident for SCCs than for ACs. Hence, SEC62 over-
expression does not just seem to be a coincident phe-
nomenon correlated with the cancerous phenotype but,
on the contrary, appears to play a functional role in the
molecular carcinogenesis of lung cancer.Functional Approaches Reveal a Crucial Role of
SEC62 Overexpression in Cancer Cell Biology
To find out how Sec62 promotes the neoplastic transfor-
mation of human cells, we performed different cell culture
experiments using various cell lines. On the basis of our
previous studies with prostate cancer cells, we examined
the effects of SEC62 silencing on migration and ER stress
tolerance of lung and thyroid cancer cell lines. As previ-
ously reported for PC3 cells,26 we found a distinct inhi-
bition of migration potential and ER stress tolerance in
different human lung and thyroid cancer cell lines after
RNA interference–based reduction of the Sec62 protein
level. Moreover, we showed that in agreement with our
finding of increased Sec62 content in metastasized tu-
mors, overexpression of SEC62 clearly stimulated the
migrative potential of HEK293 cells.
On the basis of these results, tumor cells may benefit
from an increased Sec62 level in terms of a pronounced
capability to migrate and thus to metastasize and of a
higher efficiency to cope with ER stress, which exists at a
persistently high level in tumor tissue due to elevated
proliferation and hypoxic metabolic conditions.37–39 The
exact mechanisms by which Sec62 influences these mo-
lecular processes remain unknown. Because Sec62 is
suggested to play a role in protein translocation into the
Figure 5. Effects of silencing and overexpress-
ing the SEC62 gene on migration and prolifera-
tion in BC01, BHT101, ML1, and HEK293 cells.
BC01, BHT101, and ML1 cells were transfected
with SEC62 untranslated region siRNA, SEC62
siRNA, or control siRNA in 24-well plates. After
24 hours transfection was repeated, and after
another 24 hours the cells were used for the
migration and proliferation assay. For the over-
expression experiments, HEK293 cells stably
transfected with LV plasmid (control) or IRES-
GFP-SEC62 plasmid (two clones with different
increase in Sec62 protein content, termed D4 or
G2) were used. Migration was tested in the BD
Falcon FluoroBlok system in 24-well inserts. Af-
ter 72 hours, cells were fixed with methanol,
stained with DAPI, and analyzed by fluores-
cence microscopy. The proliferation of cells was
monitored using the xCELLigence system. A: Ef-
fects of SEC62 silencing and overexpression on
migration. B: Real-time proliferation analysis us-
ing the xCELLigence system. C: The amount of
Sec62 was measured after SDS-PAGE and West-
ern blotting of an aliquot taken from the cells
that were seeded on the FluoroBlok inserts and
the ePlate96. GAPDH was used as a loading
control. All experiments were performed in
triplicate.ER, one can speculate that the inhibition of cell migration
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be due to a reduced biogenesis of specific membrane
proteins or secretory proteins being involved in cell mi-
gration. In addition, SEC62 silencing in HeLa cells in our
previous study led to an elevated basal level of cytosolic
calcium and to a considerably higher increase of the
cytosolic calcium concentration after treatment with thap-
sigargin, compared with cells with normal Sec62 levels.25
Thus, we suggest that besides migration, Sec62 may
influence various other cellular processes, including ER
stress tolerance, apoptosis, and unfolded protein re-
sponse induction by affecting cellular calcium homeosta-
sis. Previously, we induced ER stress in prostate cancer
cells using either thapsigargin, a SERCA inhibitor, or tu-
nicamycin, which blocks the formation of N-linked glyco-
proteins. Results showed that Sec62 depletion resulted in
higher sensitivity to thapsigargin- but not tunicamycin-
induced ER stress.25 Thus, the protective effect of Sec62
seems to be limited to ER stress induced by changes in
the cellular calcium level. Alternatively, Sec62 overpro-
duction in tumor cells may allow for facilitated transloca-
tion of certain precursor proteins into the ER and, there-
fore, stimulate cellular activities, such as cell migration
and ER stress response. This proliferative advantage of
Sec62 overproduction might be attenuated by drugs,
such as apratoxin A, that inhibit the co-translational trans-
location of proteins into the ER.40 Future research will be
needed to explore the exact mechanisms by which
Sec62 influences these processes.
Sec62 as a Prognostic Marker and Therapeutic
Target in NSCLC Patients
The conclusions of this study indicate that Sec62 is a
promising new candidate for a prognostic marker in
NSCLC patients. Other studies showed that 3q amplifi-
cation is characteristic of the transition from severe dys-
plasia to invasive SCC of the uterine cervix.41,42 Although
the data in our study were not statistically significant, we
observed a trend of higher Sec62 levels in more ad-
vanced cases by comparing the qPCR and Western blot
data with the Union for International Cancer Control stag-
ing of the examined tumors. To determine whether Sec62
can actually serve as a prognostic marker in NSCLC
patients, further studies should primarily include larger
populations and the clinical follow-up of the patients in-
cluded in this study.
Beyond that, Sec62 might also serve as a therapeutic
target for the treatment of NSCLC patients. The applica-
tion of small RNAs in cancer therapy has been intensively
studied,43 and it is possible that the RNA interference–
based decrease in Sec62 protein level, as described in
this study, could be used as a therapeutic tool. A reduc-
tion in the Sec62 content of tumor cells could inhibit their
capability to migrate and thus to metastasize, as well as
limit their proliferation rate via enhanced sensitization to
ER stress. In the case of lung cancer, therapeutic small
RNA could be applied as an aerosol, thus avoiding re-
ported delivery problems, such as an inefficient siRNA
uptake by the cancer cells and insufficient selectivity oftoxic effects.44 Because we have shown that increased
SEC62 mRNA and protein levels are more frequent in
SCC than in AC, Sec62-targeted therapy would espe-
cially be appropriate for the treatment of SCC patients.
Almost all recently developed molecular therapies (eg,
the inhibition of vascular endothelial growth factor by
bevacizumab,45 epidermal growth factor receptor by ge-
fitinib,7 and anaplastic lymphoma kinase by crizotinib46)
are limited to treatment of AC cases, emphasizing the
urgent need for new strategies for the treatment of SCC
patients. In addition, for determining a personalized ther-
apeutic approach, monitoring Sec62 protein levels could
be a powerful predictive marker. Patients with a low
Sec62 protein level—in the case of lung cancer, mostly
AC patients—would benefit from a therapy using thapsi-
gargin or analog agents, which are considered for cancer
therapy in recent reports,47,48 whereas tumor cells with
high Sec62 protein levels are protected against such
therapeutics. Interestingly, in this context, several groups
reported that a fusion protein of SubA, a bacterial toxin
that cleaves BiP as the key element of unfolded protein
response, and the epidermal growth factor forms an ef-
fective killer of epidermal growth factor receptor–positive
tumor cells,49,50 which are predominantly found in ade-
nocarcinoma of the lung. Sec62, as an indicator for ER
stress tolerance of tumor cells, could be useful as a
predictive marker for such therapeutic approaches and
possibly as a therapeutic target.
All things considered, and with regard to the entire
field of molecular oncology, this study has identified one
more player in the complex network of tumor cell biology.
We characterized the functional role of Sec62 within car-
cinogenesis and cancer cell biology and evaluated its
relevance as a potential prognostic marker and therapeu-
tic target in lung cancer.
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